Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9HL
|
|||
| Former ID |
DNCL002933
|
|||
| Drug Name |
Vildagliptin/metformin
|
|||
| Synonyms |
274901-16-5; (S)-1-[2-((5S,7S)-3-hydroxy-adamantan-1-ylamino)-acetyl]-pyrrolidine-2-carbonitrile; 1044676-63-2; vildaglipitin; (-)-(2S)-1-[[(3-Hydroxytricyclo[3.3.1.1[3,7]]dec-1-yl)amino]acetyl]pyrrolidine-2-carbonitrile; (S)-1-[N-(3-hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile; CHEMBL319819; SCHEMBL16155482; SCHEMBL16153676; SCHEMBL10031674; CHEMBL3084811; MolPort-020-006-001; (S)-1-(2-(((1r,3R,5R,7S)-3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; BDBM123776
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 3 | [1] | |
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H25N3O2
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
|
|||
| InChI |
1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12-,13+,14-,16?,17?/m0/s1
|
|||
| InChIKey |
SYOKIDBDQMKNDQ-HHUWHTLVSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01518101) Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.